Amgen and Allergan have reported positive data from a comparative clinical trial of ABP 798 to treat patients with CD20-positive B-cell non-Hodgkin’s lymphoma.

The randomised, double-blind comparative JASMINE study evaluated the efficacy and safety of biosimilar candidate ABP 798 compared to Rituxan in lymphoma patients.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

A total of 256 adult patients were enrolled and randomised for the trial to receive either ABP 798 or rituximab at a dose of 375mg/m².

ABP 798 was administered as an intravenous (IV) infusion once weekly for four weeks followed by dosing at weeks 12 and 20.

The trial’s primary endpoint was an assessment of overall response rate (ORR) by week 28.

It was found to be within the prespecified margin for ABP 798 compared to Rituxan and highlighted clinical equivalence.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Amgen Research and Development executive vice-president David Reese said: “Today’s results with ABP 798 demonstrate another positive development from Amgen’s robust pipeline of biosimilar medicines and we look forward to working with regulatory agencies to bring this treatment to patients.

“We continue to leverage our deep expertise and heritage in biologics across innovative and biosimilar medicines as part of our commitment to providing a range of treatment options for patients with the most serious diseases, including cancer.”

The latest trial of ABP 798 is the second of two studies aimed at supporting regulatory submissions for the drug candidate.

Amgen carried out the first study in patients with moderate-to-severe rheumatoid arthritis (RA).

In January, Amgen and Allergan reported positive top-line results from a Phase l/lll trial of ABP 798 in comparison with rituximab to treat patients with moderate-to-severe RA.

Amgen has ten biosimilars in its portfolio, including three approved in the US.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact